Adherence to treatment with erythropoiesis stimulating agents

Authors

  • C. Pérez Díez Servicio de Farmacia. Hospital Universitario Miguel Servet. Zaragoza.
  • H. Navarro Aznárez Servicio de Farmacia. Hospital Universitario Miguel Servet. Zaragoza.
  • L.M. Lou Arnal Servicio de Nefrología. Hospital Universitario Miguel Servet. Zaragoza.

DOI:

https://doi.org/10.23938/ASSN.0858

Keywords:

Anemia. Chronic kidney failure. Therapeutic adherence. Erythropoietin. Epoetin alfa.

Abstract

Background. To establish adherence to treatment with erythropoiesis stimulating agents (ESA) in patients with anemia associated to chronic kidney disease (CKD), and analyze its relationship to response to ESA.

Methods. Retrospective study of a cohort of 198 patients with CKD who started treatment with epoetin-β or darbepoetin-α, followed for two years. Basal characteristics, effectiveness (% of hemoglobin (Hb) target attainment, percentage increase of Hb) and adherence (medication possession rate) were registered. A non-adherent patient was one whose mean adherence was <90%.

Results. Average global adhesion was 89.6%, slightly higher in treatment with darbepoetin α than with epoetin β; 8.6% of patients were non-adherents. Hb target was accomplished in 87% cases. Level of response to ESA treatment was independent of the degree of adherence to treatment.

Conclusions. Adherence to ESA treatment was good, without differences related to degree of response.

Downloads

Download data is not yet available.

References

CASES A, EGOCHEAGA MI, TRANCHEC S, PALLARÉS V, OJEDA R, GÓRRIZ JL, PORTOLÉS JM. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología. Nefrología 2018; 3: 8-12. https://doi.org/10.1016/j.nefro.2017.09.004

GOROSTIDI M, SANTAMARÍA R, ALCÁZAR R, FERNÁNDEZ-FRESNEDO G, GALCERÁN JM, GOICOECHEA M et al. Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica. Nefrología 2014; 34: 302-316. https://doi.org/10.3265/Nefrologia.pre2014.Feb.12464

LÓPEZ GÓMEZ JM. Manejo de la anemia en la enfermedad renal crónica. Nefrología 2008; 28: 63-66.

Ficha técnica de Aranesp®. Breda: Amgen Europe 2006. https://cima.aemps.es/cima/dochtml/ft/01185083/FT_01185083.html

Ficha técnica de Neorecormon®. Grenzach-Wyhlen: Roche Registration GmbH 2007. https://cima.aemps.es/cima/dochtml/ft/97031032/FT_97031032.html

JOHNSON DW, POLLOCK CA, MACDOUGALL IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology 2007; 12: 321-330. https://doi.org/10.1111/j.1440-1797.2007.00810.x

CHAN K, MORAN J, HLATKY M, LAFAYETTE R. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2009 Jun;24(6):1956-1962. https://doi.org/10.1093/ndt/gfn780

LO WK. Latest strategy in renal anemia management in peritoneal dialysis patients. Perit Dial Int 2008; 28: S76-80.

RODRÍGUEZ-CHAMORRO MA, GARCÍA-JIMÉNEZ E, AMARILES P, RODRÍGUEZ-CHAMORRO A, FAUS MJ. Revisión de test de medición del cumplimiento terapéutico utilizados en la práctica clínica. Aten Primaria 2017; 49: 459-64. https://doi.org/10.1157/13125407

PAGÈS-PUIGDEMONT N, VALVERDE-MERINO MI. Métodos para medir la adherencia terapéutica. Ars Pharm 2018; 59: 163-172. http://doi.org/10.30827/ars.v59i3.7387.

Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter Suppl 2012; 2: 279-335. https://doi.org/10.1016/j.kisu.2017.10.001

YEAW J, BENNER JS, WALT JG, SIAN S, SMITH DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15: 728-740. https://doi.org/10.18553/jmcp.2009.15.9.728

WAZNY LD, STOJIMIROVIC BB, HEIDENHEIM P, BLAKE PG. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002; 40: 623-628. https://doi.org/10.1053/ajkd.2002.34925

ALBERO MOLINA MD, LÓPEZ-MENCHERO MARTÍNEZ R, DEL POZO FERNÁNDEZ C, ÁLVAREZ FERNÁNDEZ L, SÁNCHEZ RODRÍGUEZ L. Eficiencia de la administración mensual subcutánea de metoxi-polietilenglicol epoetina β (Mircera®) en pacientes estables en hemodiálisis previamente tratados con eritropoyetina semanal. Dial Traspl 2013; 34: 93-100. https://doi.org/10.1016/j.dialis.2012.08.005

ROSSERT J, LEVIN A, ROGER SD, HORL WH, ROUQUERAY B, GASSMANN-MAYER C, FREI D et al. Effect of early conrrection of anemia on the progression of CKD. Am J Kidney Dis 2006; 47: 738-750. https://doi.org/10.1053/j.ajkd.2006.02.170

Published

2020-04-20

How to Cite

1.
Pérez Díez C, Navarro Aznárez H, Lou Arnal L. Adherence to treatment with erythropoiesis stimulating agents. An Sist Sanit Navar [Internet]. 2020 Apr. 20 [cited 2026 Jan. 29];43(1):81-5. Available from: https://recyt.fecyt.es/index.php/ASSN/article/view/77384

Issue

Section

Short articles

Most read articles by the same author(s)

Similar Articles

<< < 11 12 13 14 15 16 17 18 19 20 > >> 

You may also start an advanced similarity search for this article.